Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: IEEE Trans Biomed Eng. 2016 Dec 8;64(3):519–527. doi: 10.1109/TBME.2016.2637828

Fig. 5. A neutralizing antibody against TGF-β can abrogate the invasion-boosting effects of microglia.

Fig. 5

(A) Experimental data from the invasion assay in [9]. The graph shows the number of migrating glioma cells in the absence (Ctrl) or presence (MG) of microglia after introducing anti-TGF-β mAb. In the absence of antibody, the number of invading tumor cells more than doubled from the control case (Ctrl-Ab) in the presence of migroglia (MG−Ab). However, addition of antibody reduces the number of invading glioma cells by almost 50%. (B) Simulation results. In the absence of antibody, an introduction of M1/M2 microglia (+MG−Ab) in the lower chamber Increased the number of migrating glioma cells compared to the absence of microglia (−MG−Ab). However, this invasion-promoting effect can be neutralized by adding antibody to the system. In the simulation, we set a7 = 0 (complete blocking TGF-β secretion by M1/M2).